Skip to main content

Is Vimentin the Cause or Effect of Obstructive Sleep Apnea Development?

Lung volume 198, pages 275–282 (2020)Cite this article

Abstract

Purpose

In obstructive sleep apnea (OSA), hypoxia secondary to apnea and hypopnea and the resulting systemic inflammatory response are the main causes of comorbidities. The aim of this study was to investigate the relationship between OSA and vimentin, which plays an important role in the activation of cells that synthesize inflammatory cytokines.

Materials and Methods

The study included 150 OSA patients (50 mild, 50 moderate, and 50 severe OSA) and 50 patients without OSA as a control group. Plasma vimentin levels were measured from peripheral blood samples using a commercial enzyme-linked immunosorbent assay (ELISA) kit.

Results

The OSA patients in our study had significantly higher body mass index, apnea–hypopnea index (AHI), triglyceride level, mean oxygen desaturation, and plasma vimentin levels compared to the healthy control group (p = 0.007, 0.001, 0004, 0.001, and 0.001, respectively). Plasma vimentin level was significantly higher in the moderate and severe OSA groups compared to the control and mild OSA groups (p = 0.001 for all). There was no difference between severe and moderate OSA. There were significant correlations between plasma vimentin levels and OSA patients’ AHI and mean oxygen desaturation (r = 0.46, p = 0.001; r = 0.214, p = 0.005).

Conclusion

In this study, we observed significant positive correlations between plasma vimentin level and OSA severity, weight, AHI, and mean oxygen desaturation. Vimentin may have utility as a biomarker in the follow-up and treatment of OSA.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Kapsimalis F, Basta M, Varouchakis G, Gourgoulianis K, Vgontzas A, Kryger M (2008) Cytokines and pathological sleep. Sleep Med 9(6):603–614

    Article  Google Scholar 

  2. Canto GDL, Pachêco-Pereira C, Aydinoz S, Major PW, Flores-Mir C, Gozal D (2015) Biomarkers associated with obstructive sleep apnea: a scoping review. Sleep Med Rev 23:28–45

    Article  Google Scholar 

  3. Labarca G, Campos J, Thibaut K, Dreyse J, Jorquera J (2019) Do T90 and SaO 2 nadir identify a different phenotype in obstructive sleep apnea? Sleep Breath 23(3):1007–1010

    Article  Google Scholar 

  4. Musaelyan A, Lapin S, Nazarov V, Tkachenko O, Gilburd B, Mazing A, Mikhailova L, Shoenfeld Y (2018) Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev 17(9):926–934

    CAS  Article  Google Scholar 

  5. Gong DH, Dai Y, Chen S, Wang XQ, Yan XX, Shen Y, Liu J, Yang ZK, Hu J, Yu LJ (2019) Secretory vimentin is associated with coronary artery disease in patients and induces atherogenesis in ApoE−/− mice. Int J Cardiol 283:9–16

    Article  Google Scholar 

  6. Battaglia RA, Delic S, Herrmann H, Snider NT (2018) Vimentin on the move: new developments in cell migration. F1000Research 7

  7. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG (2019) Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med: JCSM: Off Publ Am Acad Sleep Med 15(2):335

    Google Scholar 

  8. Guilleminault C (1994) Mortality and morbidity of obstructive sleep apnea syndrome: prospective studies on retrospective cohorts. Sleep Breath 557–575

  9. Lavie L (2003) Obstructive sleep apnoea syndrome–an oxidative stress disorder. Sleep Med Rev 7(1):35–51

    Article  Google Scholar 

  10. Malhotra A, White DP (2002) Obstructive sleep apnoea. Lancet 360(9328):237–245

    Article  Google Scholar 

  11. Shamsuzzaman AS, Gersh BJ, Somers VK (2003) Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290(14):1906–1914

    CAS  Article  Google Scholar 

  12. Labarca G, Gower J, Lamperti L, Dreyse J, Jorquera J (2019) Chronic intermittent hypoxia in obstructive sleep apnea: a narrative review from pathophysiological pathways to a precision clinical approach. Sleep Breath 1–10

  13. Kerget B, Araz O, Erdem HB, Akgün M (2019) The frequency of monocyte chemoattractant protein-1 gene polymorphism in obstructive sleep apnea syndrome. Lung 197(5):585–592

    CAS  Article  Google Scholar 

  14. Stradling J, Craig S, Kohler M, Nicoll D, Ayers L, Nunn A, Bratton D (2015) Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA. Thorax 70(2):181–182

    CAS  Article  Google Scholar 

  15. Araz O, Karaman A, Esdur V, Ucar EY, Subasi ID, Alper F, Akgun M (2019) The association of OSAS and uvula: the role of MRI in this egg-chicken problem in OSAS. Sleep Breath 1–6

  16. Genta PR, Sands SA, Butler JP, Loring SH, Katz ES, Demko BG, Kezirian EJ, White DP, Wellman A (2017) Airflow shape is associated with the pharyngeal structure causing OSA. Chest 152(3):537–546

    Article  Google Scholar 

  17. Dantas D, Formigoni GG, Mauad T, Silva L, Cahali M, Lorenzi-Filho G (2009) Extracellular matrix of the pharyngeal wall in sleep apnea. Otolaryngol-Head Neck Surg 141(3):P121

    Article  Google Scholar 

  18. Horvath P, Tarnoki DL, Tarnoki AD, Karlinger K, Lazar Z, Losonczy G, Kunos L, Bikov A (2018) Complement system activation in obstructive sleep apnea. J Sleep Res 27(6):e12674

    Article  Google Scholar 

  19. Lang T, Lee JP, Elgass K, Pinar AA, Tate MD, Aitken EH, Fan H, Creed SJ, Deen NS, Traore DA (2018) Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nat Comm 9(1):2223

    Article  Google Scholar 

  20. Horváth P, Lázár Z, Gálffy G, Puskás R, Kunos L, Losonczy G, Mészáros M, Tárnoki Á, Tárnoki D, Bikov A (2020) Circulating P-selectin glycoprotein ligand 1 and P-selectin levels in obstructive sleep apnea patients. Lung 1–7

  21. Lam FW, Da Q, Guillory B, Cruz MA (2018) Recombinant human vimentin binds to p-selectin and blocks neutrophil capture and rolling on platelets and endothelium. J Immunol 200(5):1718–1726

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Deng M, Luo Y, Li Y, Yang Q, Deng X, Wu P, Ma H (2015) Klotho gene delivery ameliorates renal hypertrophy and fibrosis in streptozotocin-induced diabetic rats by suppressing the Rho-associated coiled-coil kinase signaling pathway. Mol Med Rep 12(1):45–54

    CAS  Article  Google Scholar 

  23. Pákó J, Kunos L, Mészáros M, Tárnoki DL, Tárnoki ÁD, Horváth I, Bikov A (2019) Decreased levels of anti-aging klotho in obstructive sleep apnea. Rejuvenation Res

Download references

Funding

The authors received no financial support for the research and/or authorship of this article.

Author information

Affiliations

  1. Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Erzurum, Turkey

    Buğra Kerget, Ömer Araz & Metin Akgün

  2. Departmant of Pulmonary Diseases, Ağrı State Hospital, Ağrı, Turkey

    Dursun Erol Afşin

  3. Departmant of Infection Diseases and Clinical Microbiology, Health Sciences University Erzurum Regional Education and Research Hospital, Erzurum, Turkey

    Ferhan Kerget

  4. Department of Biochemistry, Ataturk University School of Medicine, 25240, Erzurum, Turkey

    Seda Aşkın

Authors
  1. Buğra Kerget
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dursun Erol Afşin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ferhan Kerget
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seda Aşkın
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ömer Araz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Metin Akgün
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Buğra Kerget.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest to the publication of this article.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kerget, B., Afşin, D.E., Kerget, F. et al. Is Vimentin the Cause or Effect of Obstructive Sleep Apnea Development?. Lung 198, 275–282 (2020). https://doi.org/10.1007/s00408-020-00341-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-020-00341-6

Keywords

  • Cause or effect
  • ELISA
  • Obstructive sleep apnea
  • Vimentin